GOAL OF WORK: The aim of the study was to investigate the incidence of herpes simplex virus-1 (HSV-1) infection in mucositis during head and neck cancer radiotherapy. PATIENTS AND METHODS: Sixty patients with malignant head and neck tumor, eligible to receive radiotherapy, who were referred to the Dental Oncology Unit, entered the study. Sixteen patients (26.6%) received concomitant chemotherapy. Mucositis was recorded weekly. Smears taken from the ulcers of mucositis grade 2, or 3, or 4 were stained with Papanicolaou and alkaline phosphatase/antialkaline phosphatase immunocytochemical method to identify HSV-1. MAIN RESULTS: Forty-eight of all 60 patients developed ulcerative mucositis. Smear was available from 29 of 48 patients with ulcerations. HSV-1 infection was identified in 14 of 29 smears available (48.2%). Mucositis healed or was reduced after 1 week of antiviral treatment in 11 of those 14 HSV-1-positive patients; 3 patients responded to 1 g/day of valacyclovir, 7-2 g/day, and 1 patient responded to i.v. acyclovir. Ulcerations recurred after quitting antivirals. Three patients did not respond to 1 g/day of valacyclovir. No HSV-1-negative patient responded to acyclovir (P = 0.000). CONCLUSION: HSV-1 was isolated from 14 of 29 available smears taken from 48 patients with ulcerative mucositis. The incidence of HSV-1 infection during radiotherapy was estimated as being 14 of all 48 patients at risk (29.1%). Healing or reduction in the grade of mucositis after antivirals in HSV-1 positive patients, combined with the negative response to antivirals in HSV-1 negative patients, denoted that HSV-1 infection was a component of ulcerative radiation mucositis in those HSV-1-positive patients.
GOAL OF WORK: The aim of the study was to investigate the incidence of herpes simplex virus-1 (HSV-1) infection in mucositis during head and neck cancer radiotherapy. PATIENTS AND METHODS: Sixty patients with malignant head and neck tumor, eligible to receive radiotherapy, who were referred to the Dental Oncology Unit, entered the study. Sixteen patients (26.6%) received concomitant chemotherapy. Mucositis was recorded weekly. Smears taken from the ulcers of mucositis grade 2, or 3, or 4 were stained with Papanicolaou and alkaline phosphatase/antialkaline phosphatase immunocytochemical method to identify HSV-1. MAIN RESULTS: Forty-eight of all 60 patients developed ulcerative mucositis. Smear was available from 29 of 48 patients with ulcerations. HSV-1 infection was identified in 14 of 29 smears available (48.2%). Mucositis healed or was reduced after 1 week of antiviral treatment in 11 of those 14 HSV-1-positive patients; 3 patients responded to 1 g/day of valacyclovir, 7-2 g/day, and 1 patient responded to i.v. acyclovir. Ulcerations recurred after quitting antivirals. Three patients did not respond to 1 g/day of valacyclovir. No HSV-1-negative patient responded to acyclovir (P = 0.000). CONCLUSION: HSV-1 was isolated from 14 of 29 available smears taken from 48 patients with ulcerative mucositis. The incidence of HSV-1 infection during radiotherapy was estimated as being 14 of all 48 patients at risk (29.1%). Healing or reduction in the grade of mucositis after antivirals in HSV-1 positive patients, combined with the negative response to antivirals in HSV-1 negative patients, denoted that HSV-1 infection was a component of ulcerative radiation mucositis in those HSV-1-positive patients.
Authors: J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason Journal: J Histochem Cytochem Date: 1984-02 Impact factor: 2.479
Authors: O Nicolatou-Galitis; K Dardoufas; P Markoulatos; A Sotiropoulou-Lontou; K Kyprianou; G Kolitsi; G Pissakas; C Skarleas; V Kouloulias; V Papanicolaou; N J Legakis; A Velegraki Journal: J Oral Pathol Med Date: 2001-09 Impact factor: 4.253
Authors: O B Wijers; P C Levendag; E R Harms; A M Gan-Teng; P I Schmitz; W D Hendriks; E B Wilims; H van der Est; L L Visch Journal: Int J Radiat Oncol Biol Phys Date: 2001-06-01 Impact factor: 7.038
Authors: Edward B Rubenstein; Douglas E Peterson; Mark Schubert; Dorothy Keefe; Deborah McGuire; Joel Epstein; Linda S Elting; Philip C Fox; Catherine Cooksley; Stephen T Sonis Journal: Cancer Date: 2004-05-01 Impact factor: 6.860
Authors: Rajesh V Lalla; Marie C Latortue; Catherine H Hong; Anura Ariyawardana; Sandra D'Amato-Palumbo; Dena J Fischer; Andrew Martof; Ourania Nicolatou-Galitis; Lauren L Patton; Linda S Elting; Fred K L Spijkervet; Michael T Brennan Journal: Support Care Cancer Date: 2010-05-08 Impact factor: 3.603
Authors: Sharon Elad; Vinisha Ranna; Anura Ariyawardana; Maria Elvira Pizzigatti Correa; Vanessa Tilly; Raj G Nair; Tanya Rouleau; Richard M Logan; Andres Pinto; Veronica Charette; Debbie P Saunders; Siri Beier Jensen Journal: Support Care Cancer Date: 2016-11-16 Impact factor: 3.603
Authors: Sharon Elad; Yehuda Zadik; Ian Hewson; Allan Hovan; M Elvira P Correa; Richard Logan; Linda S Elting; Fred K L Spijkervet; Michael T Brennan Journal: Support Care Cancer Date: 2010-06-11 Impact factor: 3.603
Authors: Regina Maria Holanda de Mendonça; Marcela de Araújo; Carlos Emilio Levy; Joseane Morari; Rosângela A Silva; José Andres Yunes; Silvia Regina Brandalise Journal: Support Care Cancer Date: 2011-05-20 Impact factor: 3.603
Authors: Andreza Veruska Lira Correia; Maria Rosângela Cunha Duarte Coêlho; Georgea Gertrudes de Oliveira Mendes Cahú; Jéfferson Luis de Almeida Silva; Catarina da Mota Vasconcelos Brasil; Jurema Freire Lisboa de Castro Journal: Support Care Cancer Date: 2014-12-30 Impact factor: 3.603
Authors: Arsinoi Xanthinaki; Ourania Nicolatou-Galitis; Pavlina Athanassiadou; Maria Gonidi; Vassilis Kouloulias; Anastasia Sotiropoulou-Lontou; George Pissakas; Konstantinos Kyprianou; John Kouvaris; Efstratios Patsouris Journal: Support Care Cancer Date: 2008-01-16 Impact factor: 3.603